参考文献/References:
[1] Hammond MEH,Hayes DF,Dowestt M,et al.American Society of clinical Oncology/College of American Pathologists guideline recommendations for immuno-histochemical testing of estrogen and progesterone receptors in breast cancer[J].Journal of Oncology Practice,2010,6(4):195-197.
[2] 赵淑红,曹席明,于 娇,等.转移性三阴乳腺癌89例临床特点及生存分析[J].陕西医学杂志,2016,45(7):859-861.
[3] 郑桂兰,李英杰,赵 月,等.乳癌术后巩固方对三阴乳腺癌术后生活质量的影响[J].陕西中医,2016,37(11):1494-1495.
[4] Wolff AC,Hammond ME,Hicks DG,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J].Journal of Clinical Oncology,2013,31(31):3997-4013.
[5] Tan AR,Swain SM.Therapeutic strategies for triple-negative breast cancer[J].Cancer J,2008,14(6):343-351.
[6] Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2017,13(15):4429-4434.
[7] Murria R,Palanca S,de Juan I,et al.Immunohistochemical,genetic and epigenetic profiles of hereditary and triple negative breast cancers.Relevance in personalized medicine[J].American Journal of Cancer Research,2015,5(7):2330-2343.
[8] Lehmann BD,Bauer JA,Chen X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J].J Clin Invest,2011,121(7):2750-2767.
[9] Thike AA,Yong-Zheng CL,Cheok PY,et al.Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer[J].Mod Pathol,2014,27(3):352-360.
[10] Park S,Koo J,Park HS,et al.Expression of androgen receptors in primary breast cancer[J].Ann Oncol,2010,21(3):488-492.
[11] ACR.BI-RADS Atlas Breast imaging reporting and data system[M].5th ed.Reston:American College of Radiotogy,2013:1-246.
[12] Lee YJ,Choi SY,Kim KS,et al.Variability in observer performance between faculty members and residents using breast imaging reporting and data system(BI-RADS)-ultrasound,fifth edition(2013)[J].Iran J Radiol,2016,13(3):e28281.
[13] Turner NC,Reis-Filho JS.Tackling the diversity of triple-negative breast cancer[J].Clin Cancer Res,2013,19(23):6380-6388.
[14] Hu R,Dawood S,Holmes MD,et al.Androgen receptor expression and breast cancer survival in postmenopausal women[J].Clin Cancer Res,2011,17(7):1867-1874.
[15] 张惠美,徐华军,毛新峰,等.雄激素受体表达阳性与阴性的三阴乳腺癌的钼靶X线特征[J].中国医学影像技术,2018,34(9):1368-1371.
[16] Gucalp A,Tolaney S,Isakoff SJ,et al.Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive,estrogen receptor-negative metastatic breast cancer[J].Clin Cancer Res,2013,19(9):5505-5512.
[17] Luck AA,Evans AJ,James JJ,et al.Breast carcinoma with basal phenotype:mammographic findings [J].AJR Am J Roentgenol,2016,191(2):346-351.
[18] Krizmanich-Conniff KM,Paramagul C,Patterson SK,et al.Triple receptor-negative breast cancer:imaging and clinical charac-teristics[J].AJR Am J Roentgenol,2015,199:458-464.
[19] Ryu EB,Chang JM,Seo M,et al.Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound[J].Eur Radiol,2014,24:2227-2235.
相似文献/References:
[1]苏 成,李 斌,王可为△.术前新辅助化疗对三阴性乳腺癌患者血清Ki67、PDL1表达的影响*[J].陕西医学杂志,2019,(12):1605.
SU Cheng,LI Bin,WANG Kewei..Effects of preoperative neoadjuvant chemotherapy on serum Ki67 and PDL1 expression in patients with triple negative breast cancer[J].,2019,(12):1605.
[2]祝景伟,佟经伟,许培权△.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义[J].陕西医学杂志,2020,49(8):940.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.007]
ZHU Jingwei,TONG Jingwei,XU Peiquan..Expression and significance of TAZ and YAP in Hippo signaling pathway in triple negative breast cancer[J].,2020,49(12):940.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.007]
[3]李秀华,唐冬梅,朱丽萍,等.三阴性乳腺癌临床病理特征与基因分型研究[J].陕西医学杂志,2021,50(8):1015.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.028]
LI Xiuhua,TANG Dongmei,ZHU Liping,et al.Clinicopathological features and genotyping of triple negative breast cancer[J].,2021,50(12):1015.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.028]
[4]徐英杰,李 巍.三阴性乳腺癌早期患者雄激素受体、Ki67、p53、表皮生长因子受体表达水平及其与临床病理特征关系研究[J].陕西医学杂志,2021,50(12):1594.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.032]
XU Yingjie,LI Wei.Expression levels of androgen receptor,Ki67,p53,epidermal growth factor receptor and their relationship with clinicopathological characteristics in early stage triple-negative breast cancer patients[J].,2021,50(12):1594.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.032]